A doxorubicin-CNGRC-peptide conjugate with prodrug properties

Biochemical Pharmacology

Volumn 63, Issue 5, 2002, Pages 897-908

  Van Hensbergen, Yvette ^a   Broxterman, Henk J ^a   Elderkamp, Yvonne W ^a   Lankelma, Jan ^a   Beers, Judith C C ^a   Heijn, Marc ^a   Boven, Epie ^a   Hoekman, Klaas ^a   Pinedo, Herbert M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aminopeptidase N; CD13; Doxorubicin; Doxorubicin peptide conjugate; Prodrug; Tumor vasculature

Indexed keywords

DOXORUBICIN; DOXORUBICIN CYSTYLASPARAGINYLGLYCYLARGINYLCYSTEINAMIDE CONJUGATE; MICROSOMAL AMINOPEPTIDASE; PEPTIDE DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UMBILICAL VEIN; XENOGRAFT;

ANIMALS; ANTIGENS, CD13; ANTINEOPLASTIC AGENTS; CELL DIVISION; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG CARRIERS; DRUG STABILITY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; PRODRUGS; SUBCELLULAR FRACTIONS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036497249     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00928-5     Document Type: Article

References (40)

1. Anthracycline resistance: The problem and its definition
2. The anthracyclines: Will we ever find a better doxorubicin?
3. Understanding the barriers to drug delivery: High resolution in vivo imaging is key
4. Doxorubicin gradients in human breast cancer
5. Cellular membrane permeability of anthracyclines does not correlate with their delivery in a tissue isolated tumor
6. Liposomal formulations of anticancer agents: Selectivity and effectiveness
7. Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts
8. Anticancer drug targets: Approaching angiogenesis
9. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
10. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N
11. Structure and expression of aminopeptidase N
12. Expression of aminopeptidase-N (CD13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin
13. The 140-kDa protein of blood-brain barrier-associated pericytes is identical to aminopeptidase N
14. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation
15. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
16. Anti-cancer activity of targeted pro-apoptotic peptides
17. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
18. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
19. Anti-angiogenesis therapy: Concepts and importance of dosing schedules in clinical trials
20. Culture and characterization of human endothelial cells
21. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent
22. New method for the determination of doxorubicin, 4′-epidoxorubicin and all known metabolites in cardiac tissue
23. Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection
24. Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain
25. CD-13 (gp150, aminopeptidase N): Co-expression on endothelial and hematopoietic cells with conservation of functional activity
26. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: Distribution and efficacy in experimental human ovarian cancer
27. Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer
28. The monoclonal antibody ER-BMDM1 recognizes a macrophage and dendritic cell differentiation antigen with aminopeptidase activity
29. Expression of aminopeptidase N (CD13) in mesenchymal tumors
30. Peptide-guided cancer drugs show promise in mice
31. Direct activation of caspases by RGD-peptides may increase drug sensitivity of tumour cells
32. Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin
33. Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel: Selective activation by the tumor-associated protease plasmin
34. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas
35. The antennapodia peptide penetratin translocates a crosslipid bilayers - The first direct observation
36. Structure of the human oxytosinase/insulin-regulated aminopeptidase gene and localization to chromosome 5q21
37. Bestatin as an experimental tool in mammals
38. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
39. + cells
40. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines